复星医药向专业投资者公开发行公司债券获中国证监会注册批复

Core Viewpoint - Fosun Pharma has received approval from the China Securities Regulatory Commission (CSRC) to publicly issue technology innovation corporate bonds with a total face value of up to RMB 6 billion [1] Group 1 - The approval is documented in the CSRC's official notice, indicating the company's compliance with regulatory requirements [1] - The registered bonds can be issued in tranches within a validity period of 24 months from the date of approval [1] - The issuance is targeted at professional investors, reflecting the company's strategy to raise funds for technological innovation [1]